StockDrifts LogoStockDrifts

Kai Biotech 446600

Company
카이바이오텍Kai Biotech
Insiders
0
Buys
0
Total Value
—
Avg Return
—
Last Filing
2024-09-12

Kai Biotech (446600) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Kai Biotech is dated 2024-05-03; the most recent is 2024-09-12.

Price & insider activity (12 months)

No price data available

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2024-09-12BUY장외매수
새한산업
Saehan Industry
-136.4K₩6,340+136.6%₩865M ($600K)
2024-05-03BUY장외매수
김영덕
Youngdeok Kim
CEO45.5K₩6,340+136.6%₩288M ($200K)

Frequently asked questions

Who has been buying Kai Biotech stock?
0 distinct insiders have filed 0 disclosed insider purchases in Kai Biotech (446600), most recently on 2024-09-12. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Kai Biotech have?
Kai Biotech has 0 buy-side and 0 sell-side disclosures on record, spanning 2024-05-03 to 2024-09-12.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.